North Bay Business Journal -- NOVATO — BioMarin Pharmaceutical Inc. will allow its marketing partnership for the drug Aldurazyme to remain in place with Sanofi-Aventis following the French drug maker’s $20 billion acquisition of Genzyme Corp. BioMarin explored exercising a change-0f-control provision in its agreement with Genzyme, the Novato company said in a filing with regulators. Under that provision BioMarin could have set its own price for full rights to Aldurazyme, which brings revenues of about $250,000 a year.
